Progress in Prostate Cancer: A Focus on PARP Inhibitors

Share

Program Content

  • Focus on PARP Inhibitors
    Progress in Prostate Cancer: A Focus on PARP Inhibitors
    Slideset
    Congratulations: You achieved a completion on 04/09/2022
    View Activity

Supporters

AstraZeneca

Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Merck Sharp & Dohme Corp